TSXV:BTI.H - Post by User
Comment by
BearDownAZon Jul 31, 2015 9:25pm
122 Views
Post# 23982012
RE:RE:News Alert
RE:RE:News AlertOn Armagen's website for their Hunter Syndrome MPS II program, they site this paper in which they administered their HIRMAb-IDS fusion protein to Rhesus monkeys. One key phrase in the abstract is:
"The IDS enzyme activity in plasma was elevated 10-fold above the endogenous level, and therapeutic plasma concentrations were generated in vivo. The uptake of the HIRMAb-IDS fusion protein in the brain was sufficiently high to produce therapeutic concentrations of IDS in the brain following IV administration of the fusion protein."
https://www.ncbi.nlm.nih.gov/pubmed/21351076
"Therapeutic concentrations"......is a very vague statement. If Armagen was able to move to the clinic off of therapeutic concentrations, I don't see why Bioasis can't as well.
A couple other points:
1) The Bioasis study was in mice. Are primate studies necessary prior to Bioasis proceeding to humans? It's also possible that the Transcendpep works better in primates than humans.
2) The Armagen approach achieved 1% of the inject dose into the brain (https://www.ncbi.nlm.nih.gov/pubmed/24059813). So if the Transcendpep approach is 6-fold better than the Armagen human IR-antibody approach, then it seems obvious that the Transcendpep approach should work not only equally well, but better.